step up trial semaglutide UP: 7.2mg achieves 20.7% weight loss and 18.7% regardless of treatment adherence Semaglutide versus placebo in individuals
Description
Severe or persistent reactionsspreading erythema, deep tissue swelling, signs of infection, or allergic responsewarrant immediate provider contact
PubMed Rosenstock J, et al
As of June 30, 2025: [Google Scholar]
remote care enables timely dose adjustments without the need for travel
Between 2023 and 2045, many key patents will expire, opening the door to generics and forcing originators to diversify protection strategies
Important: Lifestyle strategies may help reduce common digestive symptoms, but they cannot guarantee that side effects will not occur
